CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

Bacterial Lysates

Trade name: pulmonarom

Biologicalexperimental

Picibanil also called OK - 432, is a mixture of group A streptococcus with anti-neoplastic properties used in treatment of cystic hygroma (lymphangiomas). — Wikipedia

Clinical trial activity

20 trials · 33 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
12
Phase 3
8
Phase 4
6

Earliest trial started Jan 1, 1998 (NCT03427619)

Timeline

2000s

  1. Jan 1, 2003

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2024

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • bacterial immunostimulant
  • bacterial lysate
  • broncho-vaxom
  • broncho-vaxom
  • imocur
  • ismigen
  • ismigen
  • om-85
  • om-85 bv
  • polyvalent mechanical bacterial lysate
  • pulmonarom

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06486662Phase 1Jun 14, 2024OM Pharma
NCT05857930Phase 2Jun 20, 2023OM Pharma
NCT05677763Phase 4Dec 12, 2022OM Pharma
NCT05222516Phase 2Dec 20, 2021OM Pharma
NCT05063149Phase 3Oct 31, 2021Franciscus Gasthuis, Leiden University, Maastricht University
NCT05044169N/ASep 30, 2021Anhui Medical University, Anhui Province Cancer Hospital
NCT04802616Phase 3Mar 22, 2021Medical University of Lublin
NCT04496245Phase 3Aug 24, 2020Griffith University, Queensland Children's Hospital, Telethon Kids Institute, University of Queensland, University of Sydney
NCT04129931Phase 2Nov 30, 2019National Heart, Lung, and Blood Institute (NHLBI), University of North Carolina at Chapel Hill
NCT04270552Phase 3Apr 22, 2018Medical University of Lublin
NCT04637425Phase 3Apr 22, 2018Medical University of Lublin
NCT03243565Phase 4Nov 1, 2017Dr. Sami Ulus Children's Hospital
NCT02148796Phase 2Jan 3, 2017Pennsylvania State University, University of Arizona
NCT01968421Phase 3Mar 1, 2015Capital Medical University, China Medical University, Chinese Academy of Medical Sciences, Huazhong University of Science and Technology, Nanjing Medical University, Peking University, Tsinghua University, Zhejiang University
NCT02541331Phase 3Jul 1, 2014Lallemand SAS
NCT02417649Phase 4Sep 1, 2009Lallemand SAS, Sprim Consulting, University of Geneva
NCT00599417Phase 4Dec 1, 2007Sanofi
NCT00733226Phase 4Aug 1, 2007Kecioren Education and Training Hospital
NCT03047954Phase 3Jul 1, 2003University of Paris, Vifor Inc.
NCT03427619Phase 4Jan 1, 1998University of Iowa
Showing 20 of 20 trials
Page 1 / 1

Organizations

Research & Development (33)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
OM PharmaFor profit4432021
Medical University of LublinAcademic/Hospital3312018
Lallemand SASFor profit2222009
Anhui Medical UniversityAcademic/Hospital1012021
Anhui Province Cancer HospitalAcademic/Hospital1112021
Capital Medical UniversityAcademic/Hospital1012015
China Medical UniversityAcademic/Hospital1012015
Chinese Academy of Medical SciencesAcademic/Hospital1112015
Dr. Sami Ulus Children's HospitalAcademic/Hospital1112017
Franciscus GasthuisAcademic/Hospital1112021
Griffith UniversityAcademic/Hospital1012020
Huazhong University of Science and TechnologyAcademic/Hospital1012015
Kecioren Education and Training HospitalAcademic/Hospital1112007
Leiden UniversityAcademic/Hospital1012021
Maastricht UniversityAcademic/Hospital1012021
Nanjing Medical UniversityAcademic/Hospital1012015
National Heart, Lung, and Blood Institute (NHLBI)Government1012019
Peking UniversityAcademic/Hospital1012015
Pennsylvania State UniversityAcademic/Hospital1012017
Queensland Children's HospitalAcademic/Hospital1012020
33 organizations
Page 1 / 2